272 related articles for article (PubMed ID: 15795539)
1. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose.
von Beckerath N; von Beckerath O; Koch W; Eichinger M; Schömig A; Kastrati A
Blood Coagul Fibrinolysis; 2005 Apr; 16(3):199-204. PubMed ID: 15795539
[TBL] [Abstract][Full Text] [Related]
2. P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.
Bierend A; Rau T; Maas R; Schwedhelm E; Böger RH
Br J Clin Pharmacol; 2008 Apr; 65(4):540-7. PubMed ID: 17995973
[TBL] [Abstract][Full Text] [Related]
3. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene.
Staritz P; Kurz K; Stoll M; Giannitsis E; Katus HA; Ivandic BT
Int J Cardiol; 2009 Apr; 133(3):341-5. PubMed ID: 18485500
[TBL] [Abstract][Full Text] [Related]
4. Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms.
Kar R; Meena A; Yadav BK; Yadav R; Kar SS; Saxena R
Platelets; 2013; 24(4):297-302. PubMed ID: 22721490
[TBL] [Abstract][Full Text] [Related]
5. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.
Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Lambert M; Camoin L; Vague IJ; Bonnet JL; Alessi MC
Thromb Res; 2007; 120(6):893-9. PubMed ID: 17337040
[TBL] [Abstract][Full Text] [Related]
6. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF
Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210
[TBL] [Abstract][Full Text] [Related]
8. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.
Fontana P; Dupont A; Gandrille S; Bachelot-Loza C; Reny JL; Aiach M; Gaussem P
Circulation; 2003 Aug; 108(8):989-95. PubMed ID: 12912815
[TBL] [Abstract][Full Text] [Related]
9. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
Steinhubl S; Roe MT
Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
[TBL] [Abstract][Full Text] [Related]
10. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
[TBL] [Abstract][Full Text] [Related]
11. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
J Thromb Haemost; 2010 Jan; 8(1):37-42. PubMed ID: 19818001
[TBL] [Abstract][Full Text] [Related]
12. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
Savi P; Herbert JM
Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
[TBL] [Abstract][Full Text] [Related]
13. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.
Bouman HJ; Parlak E; van Werkum JW; Breet NJ; ten Cate H; Hackeng CM; ten Berg JM; Taubert D
J Thromb Haemost; 2010 Mar; 8(3):482-8. PubMed ID: 20040042
[TBL] [Abstract][Full Text] [Related]
14. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.
Jeong YH; Hwang JY; Kim IS; Park Y; Hwang SJ; Lee SW; Kwak CH; Park SW
Circ Cardiovasc Interv; 2010 Feb; 3(1):17-26. PubMed ID: 20118150
[TBL] [Abstract][Full Text] [Related]
15. Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy.
Bagoly Z; Sarkady F; Magyar T; Kappelmayer J; Pongrácz E; Csiba L; Muszbek L
PLoS One; 2013; 8(7):e69417. PubMed ID: 23844259
[TBL] [Abstract][Full Text] [Related]
16. Associations of P2Y12R gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel.
Yang HH; Chen Y; Gao CY
Cardiovasc Ther; 2016 Dec; 34(6):460-467. PubMed ID: 27566695
[TBL] [Abstract][Full Text] [Related]
17. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
Morel O; Viellard C; Faure A; Jesel L; Ohlmann P; Desprez D; Chauvin M; Roul G; Grunebaum L; Bareiss P
Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):21-9. PubMed ID: 17343035
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
Niitsu Y; Jakubowski JA; Sugidachi A; Asai F
Semin Thromb Hemost; 2005 Apr; 31(2):184-94. PubMed ID: 15852222
[TBL] [Abstract][Full Text] [Related]
19. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions.
Rudez G; Bouman HJ; van Werkum JW; Leebeek FW; Kruit A; Ruven HJ; ten Berg JM; de Maat MP; Hackeng CM
Circ Cardiovasc Genet; 2009 Oct; 2(5):515-21. PubMed ID: 20031628
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.
Kreutz RP; Nystrom P; Kreutz Y; Miao J; Kovacs R; Desta Z; Flockhart DA; Jin Y
Platelets; 2013; 24(2):145-50. PubMed ID: 22385219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]